INTRODUCTION
Interval breast cancers are cancers diagnosed in the interval between two mammographic screening visits. They are either true interval cancers (not present at screen examination) or false negatives from screening, with the latter being partly a consequence of high breast density masking a tumor on the x-ray. It is known that interval breast cancers have a more aggressive phenotype compared with screendetected cancers, with higher histologic grade, larger tumor size, higher TNM stage, more estrogen receptor (ER)/progesterone receptor (PR) negativity, [1] [2] [3] [4] [5] [6] higher proliferation rates, 2, 3, [5] [6] [7] [8] and more often a triple-negative phenotype, 2, 9 highlighting the importance of identifying women at risk. Apart from high breast density and hormone replacement therapy (HRT) use, risk factors for interval breast cancer are not well established. Studies comparing family history between interval breast cancers and screen-detected breast cancers have been inconclusive. 2, 3, 7, 8, [10] [11] [12] [13] Current HRT use has consistently been shown to be more common in interval breast cancers, [1] [2] [3] 7, 10 but whether this is explained
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by masking through increased mammographic density is not known. There is also little knowledge about associations between interval breast cancers and reproductive breast cancer risk factors. We have previously found that interval breast cancers in women with low, but not high, breast density have worse prognosis compared with screen-detected breast cancers. 14 This suggests an importance of taking mammographic density into account when studying interval breast cancers. To our knowledge, no one has yet investigated whether tumor characteristics and risk factors of interval breast cancers differ by mammographic density when compared with screen-detected breast cancers. We compared established familial, reproductive, and hormonal breast cancer risk factors, as well as tumor characteristics, between screen-detected breast cancers and interval breast cancers in a large cohort of screening program participants, assessing associations in women with high and low mammographic density separately.
PATIENTS AND METHODS
Study approval was granted by the Regional Ethical Review Board in Stockholm, Sweden (Karolinska Institutet, DNR2009/254-31/4).
Setting
Phenotypic characterization was performed in the entire population of women diagnosed with screen-detected breast cancer and interval breast cancer from 2001 to 2008 in Stockholm, Sweden. Detailed questionnaire information and mammographic images were available for participants in the Libro-1 study nested in the aforementioned population.
Participant Recruitment and Data Collection
All women diagnosed with invasive breast cancer in Stockholm from 2001 to 2008 were identified through the Stockholm-Gotland Regional Breast Cancer quality register. Women who had been eligible for participation in the population-based screening program within the last 24 months of diagnosis (age 40 to 71 years at diagnosis, n ϭ 7669) were all assessed for screening history. Dates of mammographic screening visits and information about the outcome of each visit were obtained through merges to the mammography screening database kept at the Stockholm-Gotland Regional Cancer Center. The database contains attendance and outcome of all visits undertaken within the population-based mammography screening program for Stockholm County. All Stockholm women age 50 to 69 have been invited to be screened at 24-month intervals since 1989, whereas women age 40 to 49 were included from mid-2005 and screened at 18-month intervals. Participation rate was 70%, recall rate was 3%, and detection rate was 0.5% for the study period. 15 Full details of the organizational and quality aspects of the Stockholm mammography screening program are described the publication by Lind et al. 15 Screen-detected breast cancer was defined as a breast cancer diagnosis made Flow chart of study creation, describing the initial cohort available for analysis, exclusions made, and final numbers of women with phenotype information (N ϭ 4,091) and image and risk factor data (n ϭ 1,957). BC, breast cancer. The distribution of interval cancer diagnoses in the population per each month of a 24-month screening interval, overall and by lowest and highest quartile of mammographic density. Expressed as proportion diagnosed per month (number of interval cancers diagnosed within each 30.5-day interval divided by the total number of interval cancers).
after a positive screen finding but before the next visit or end of a normal screening interval. Interval breast cancer was defined as a breast cancer diagnosis made after a negative screen but before the next visit or end of a normal screening interval. After excluding women diagnosed without a prior screening visit (n ϭ 2,504), women diagnosed after a normal screening interval had passed (n ϭ 928), and 146 women with uncertain mode of detection, 4,091 women with invasive screen-detected breast cancer or interval breast cancer were identified within the study period (Fig 1) .
Tumor characteristics were obtained from merges to the StockholmGotland Regional Breast Cancer quality register. Lymph node involvement was dichotomized into positive or negative. Tumor size was categorized as less than 20 mm, 20 to 40 mm, or more than 40 mm. ER and PR status were determined using radioimmunoassay or immunohistochemistry (IHC) with cutoff values of more than 10% positive cells for IHC and more than 0 fmol/g DNA for radioimmunoassay assays. The information was recorded as negative or positive in the register according to local laboratories and existing treatment program. Human epidermal growth factor receptor 2 (HER2) status, assessed by IHC/immunocytochemistry and confirmed by fluorescence in situ hybridization analysis if protein levels from IHC/immunocytochemistry showed 2ϩ or 3ϩ, was also recorded in the register as positive or negative. Triple-negative breast cancer was categorized based on ER, PR, and HER2 status. Information was essentially complete for tumor size and lymph node status, with less than 2% of patients with missing data, whereas more patients were missing data for ER and PR status (20%). HER2 status was included in the register from 2007 onward, with 13% of patients missing data on HER2 status. Grade was included from 2004, with 7% of patients missing data.
Detailed information on risk factors was available for women who were alive in 2009 and consented to participate in the Libro-1 study. Libro-1 was established by inviting all women in Stockholm with breast cancer who were younger than age 80 years at diagnosis and diagnosed between 2001 and 2008, as identified through Stockholm-Gotland Regional Breast Cancer quality register, to participate. Invitations were mailed out in 2009, together with informed consent documents and a link to an online questionnaire. Overall response rate was 62% (n ϭ 5,715). For this study, only invasive interval breast cancers and screen-detected breast cancers were considered (n ϭ 2,507; Fig 1) .
HRT use was classified as current, past, or never; current use was defined as having used HRT pills during year of diagnosis. Pill HRT users who went off HRT before the year of diagnosis or users of patches or injections at any time ). Percentages of missing data were 0% to 5% for all questionnaire variables, except for BRCA (10%) and family history (8%).
Analog mammographic images were collected from radiology departments and digitized with an Array 2905HD Laser Film Digitizer (Array Corp, Tokyo, Japan). Mammographic density was measured with the area-based measure previously described by Li et al. 16 Briefly, an algorithm is taught to distinguish dense area from nondense area by training on image segmentation data measured by an experienced Cumulus 17 analyst, thus mimicking Cumulus. Percent mammographic density was assessed in prediagnostic mediolateral oblique view images of the cancer-free breast and categorized into quartiles, with cutoffs at 20%, 29.5%, and 40.9% in this population. Women with contralateral breast cancer arising within 3 months of diagnosis were not assessed for density (n ϭ 163). An image matching our criteria was found for 1,957 (78%) of 2,507 individuals with questionnaire data.
Statistical Analysis
Binary logistic regression analysis was used to study tumor characteristics of interval breast cancers in the full population of patients with invasive screen-detected breast cancers or interval breast cancers (N ϭ 4,091). We performed binary logistic regression analyses of interval breast cancers versus screen-detected breast cancers within separate strata of the highest and lowest mammographic density quartiles. Differences between estimates from each stratum were assessed for each exposure using the Wald test. We also assessed differences by the overall pattern, combining estimates for tumor size, lymph spread, ER status, PR status, HER2 status, triple-negative phenotype, grade, and histology into one score. The overall differences score was obtained by calculating the observed sum of standardized differences (sum of z statistics) for log-odds ratios (ORs) of low and high mammographic density and comparing it with the null distribution using a Wald test. The null distribution was generated from 1,000 simulated data sets scrambling the outcome variable to obtain null associations. As a secondary analysis, histology was omitted from the score to assess overall pattern of differences solely for factors related to prognosis.
Interval breast cancers diagnosed in the first or second year of the 2-year interval were compared separately with screen-detected breast cancers using multinomial logistic regression with screen-detected breast cancers as the reference group (population-based study; full population, N ϭ 4,091). Differences between estimates for year 1 and year 2 interval breast cancers were assessed both separately for each exposure, using the Wald test, and overall, using the same approach of testing observed versus expected overall z statistics as described earlier for density. Sensitivity analysis was performed to assess main findings for tumor characteristics in the subgroup of women with questionnaire information.
Analysis of risk factors for interval breast cancer was performed in the cohort of women with density information (n ϭ 1,957), using binary logistic regression. All explanatory variables were first tested separately in crude and age-adjusted models. Variables significantly associated with interval breast cancer after adjusting for age (P Ͻ .05) were tested in multivariable models. To address the impact of mammographic density on estimates, logistic regression was performed in strata of the highest and lowest mammographic density quartiles. Sensitivity analysis including women with missing density information was done. To assess potential survivorship bias among women who provided risk factor information, sensitivity analysis restricted to women diagnosed from 2004 to 2008 was performed. Data management was performed using SAS version 9.4 statistical software (SAS Institute, Cary, NC). Statistical analysis was performed in SAS version 9.4 and R version 3.1.0 (www.rproject.org. 18 All statistical tests were two-sided, with a cutoff at ␣ ϭ .05.
RESULTS
We identified 4,091 women diagnosed with invasive breast cancer either through mammography screening or during a screening interval (Fig 1) . Of the 4,091 cancers, 70% (n ϭ 2,844) were screendetected breast cancers and 30% (n ϭ 1,247) were interval breast cancers. Of the interval breast cancers, 63% (n ϭ 791) were diagnosed in the second year after a mammography screen, with no apparent difference in year-wise distribution between dense and nondense breasts (Fig 2) . Overall, interval breast cancers had worse phenotype compared with screen-detected breast cancers, as measured by ORs (Table 1) . Women with questionnaire information were no different from the full cohort (Appendix Table A1 , online only). When comparing interval breast cancers according to time since last screen, interval breast Significant interactions between mammographic density and phenotype were found for lymph node involvement and HER2 status. The overall phenotype of interval breast cancers relative to screen-detected breast cancer was significantly more aggressive among the nondense breasts (Wald test for overall differences, P ϭ .004; excluding histology, P ϭ .008). The distribution of general breast cancer risk factors significantly associated with interval breast cancer is shown in Table 2 . ORs from the crude and age-adjusted analysis of general breast cancer risk factors are listed in Table 3 . Current HRT use, high mammographic density, low BMI, and family history of breast cancer were more common in patients with interval breast cancers. None of the reproductive risk factors under study or BRCA mutation status was found to be significantly different between groups, although the point estimates indicated higher risk among BRCA mutation carriers (Table 3) . In multivariable analysis (Table 4) , the OR for family history was 1.32 (95% CI, 1.02 to 1.70), after adjusting for age and mammographic density. The point estimate was higher among nondense breasts than dense breasts. The effect of current HRT use persisted after adjustments for mammographic density, BMI, and age at diagnosis (OR, 1.84; 95% CI, 1.38 to 2.44) and was present in both the lowest and highest quartile of mammographic density ( Table 4 ). The effect size associated with BMI was essentially unchanged after adjustments for mammographic density, age, and HRT use. The effect was still observed in the top quartile of mammographic density but was not present in the lowest mammographic density quartile (Table 4 ). Including women without images in the analysis did not change estimates, except that the effect of high age at menarche reached statistical significance (OR, 1.22; 95% CI, 1.02 to 1.46). In sensitivity analysis of survivor bias, the estimate for family history increased, whereas estimates for HRT weakened (Appendix Table A2 , online only).
DISCUSSION
In this study, we appraised clinicopathologic and risk factor differences between screen-detected breast cancers and interval breast cancers and the implications of mammographic density on obscuring tumors that should have been detected at screening. Interval breast cancers in nondense breasts were associated with aggressive tumor characteristics compared with screen-detected breast cancers in nondense breasts, whereas interval breast cancers in dense breasts were phenotypically more similar to dense screen-detected breast cancers. Current HRT use, BMI, and family history were risk factors associated with interval breast cancer. The distribution of tumor characteristics between interval breast cancers and screen-detected breast cancers overall was in full agreement with the literature, with interval breast cancers being larger at diagnosis and of higher grade, displaying more lymph node involvement, [1] [2] [3] [4] [5] [6] and more often being ER/PR negative, [2] [3] [4] 6 HER2 positive, 8 or triple negative. 2, 9 Interval breast cancers were not significantly different in phenotype whether they had been diagnosed 1 or 2 years after last screen. Instead, we found the interval breast cancer phenotype to differ by mammographic density, with nondense interval breast cancers having a significantly worse phenotype than dense interval breast cancers, compared with screen-detected breast cancers. In support of this, Domingo et al 19 performed a retrospective review of interval breast cancers, dividing them into true or missed, and reported true interval cancers to be associated with a worse phenotype, with true interval breast cancers also exhibiting weaker associations with mammographic density than missed interval breast cancers. Moreover, in previous work from our group, we found survival of patients with interval breast cancers to be poorer only in patients with nondense breasts, after adjusting for tumor size at diagnosis. 14 Together, these results suggest that interval breast cancers in nondense breasts are enriched for aggressive, true interval cancers.
We observed an increased risk of interval breast cancer among women with a mother or sister with breast cancer. In concordance with this, we found a two-fold increase in odds for interval breast cancer among BRCA mutation carriers, although the patient numbers were too low for these results to be conclusive. However, previous studies of BRCA mutations have found a lowered sensitivity of the mammography screening test for carriers, [20] [21] [22] in line with our results. Previous literature on family history and interval breast cancer reports conflicting results, using varying definitions of family history and low patient numbers (ranging from 47 to 375 patients with interval cancer. 2, 3, 7, 8, [10] [11] [12] [13] We found that there is a small effect of family history on the risk of interval cancer, but results will need to be confirmed in other, larger studies.
Overweight women were more likely to have screen-detected breast cancers, a finding that persisted after adjusting for age, HRT, and mammographic density. BMI has been reported to be positively associated with high-proliferating tumors 23 but negatively associated with percent mammographic density. 24 Together, this makes the BMI associations with interval detection difficult to interpret in a logistic regression setting without distinguishing true from false interval breast cancers, because an effect of BMI on growth rate is likely hidden by an opposite effect through the negative association with mammographic density. Notably, the negative association with BMI was not seen among the breasts with low density where the least favorable interval cancer phenotype was present.
We confirmed a higher risk of interval breast cancer, relative to screen-detected breast cancer, among current users of HRT, which has been previously shown in the literature. [1] [2] [3] 7, 10, 25 The association was attenuated, but not removed, after adjustments for age, mammographic density, and BMI and was present also in nondense breasts, indicating an effect beyond mere masking. During our study period, HRT users were advised to attend sporadic screening at private mammography clinics outside of the screening program, creating surveillance bias for this group, which may in part explain this phenomenon.
This study has limitations that must be acknowledged. A proportion of interval breast cancers are missed screen-detected breast cancers, partly a result of high mammographic density masking the tumor from detection. 19 Thus, we performed an analysis stratified by the highest and lowest quartile of density to obtain separate risk estimates. For the Stockholm Screening program, an estimated 22% of cancers were missed at screening.
26 BRCA status may have been misclassified if women not tested were in fact carriers, which could underestimate any true effect. For family history, we did not have information on daughters with breast cancer. This could attenuate any true effect of family history. Another limitation is that risk factor analysis may have been influenced by survivor bias because the questionnaire data were available for women still alive in 2009. If so, our results from the risk factors could underestimate any true effects relating to aggressive cancers. In sensitivity analysis restricting our risk factor analysis to patients diagnosed in 2004 or later, point estimates did not change overall. However, among the patients with nondense breasts, we saw a decrease in the effect size of current HRT use and an increase in the point estimate for family history (Appendix Table A2 ).
Our study has several strengths given the sample size and quality and quantity of data available. For main analysis of tumor characteristics, we have population-based data, giving us one of the largest interval breast cancer versus screen-detected breast cancer breast cancer cohorts hitherto studied. In addition, we have the combination of tumor characteristics, detailed questionnaire data, and area-based mammographic density measurements available for 1,957 women, enabling us to address the impact of mammographic density on prognostic factors and risk factors of interval cancers in one of the largest interval breast cancer studies to date.
In conclusion, interval breast cancers and screen-detected breast cancers show disparate clinicopathologic features and are associated with several breast cancer risk factors differently. Interval breast cancers among women with low mammographic density have the most aggressive phenotype, indicating enrichment of true interval breast cancers within this group. In the future, screening programs should shift from solely age-based to individual risk-based programs. Diagnostic modality and screening intervals for individual women could be decided based on risk factors such as mammographic density and genetic background.
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GLOSSARY TERMS
HER2/neu (human epidermal growth factor receptor 2): also called ErbB2. HER2/neu belongs to the epidermal growth factor receptor (EGFR) family and is overexpressed in several solid tumors. Like EGFR, it is a tyrosine kinase receptor whose activation leads to proliferative signals within the cells. On activation, the human epidermal growth factor family of receptors are known to form homodimers and heterodimers, each with a distinct signaling activity. Because HER2 is the preferred dimerization partner when heterodimers are formed, it is important for signaling through ligands specific for any members of the family. It is typically overexpressed in several epithelial tumors. population-based study: a study in which the patients are drawn from a defined population in a manner that is representative of the source population studied. Such a design can avoid bias arising from the selective factors that guide affected individuals to a particular medical facility, allowing for greater generalizability of the findings.
